The company seeks to overcome the limitations of targeting macrophage migration inhibitory factor by harnessing the high tumor-specificity of the disease-related isoform, oxidized macrophage migration inhibitory factor (oxMIF).

Its focus in on developing multiple proprietary drug modalities to leverage oxMIF’s potential as a target for systemic treatment of pancreatic, colorectal, ovarian and lung cancer, as well as for chronic inflammatory diseases.